Pharmacokinetic Analysis of Peptide-Modified Nanoparticles with Engineered Physicochemical Properties in a Mouse Model of Traumatic Brain Injury
Open Access
- 16 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 23 (5), 1-12
- https://doi.org/10.1208/s12248-021-00626-5
Abstract
Peptides are used to control the pharmacokinetic profiles of nanoparticles due to their ability to influence tissue accumulation and cellular interactions. However, beyond the study of specific peptides, there is a lack of understanding of how peptide physicochemical properties affect nanoparticle pharmacokinetics, particularly in the context of traumatic brain injury (TBI). We engineered nanoparticle surfaces with peptides that possess a range of physicochemical properties and evaluated their distribution after two routes of administration: direct injection into a healthy mouse brain and systemic delivery in a mouse model of TBI. In both administration routes, we found that peptide-modified nanoparticle pharmacokinetics were influenced by the charge characteristics of the peptide. When peptide-modified nanoparticles are delivered directly into the brain, nanoparticles modified with positively charged peptides displayed restricted distribution from the injection site compared to nanoparticles modified with neutral, zwitterionic, or negatively charged peptides. After intravenous administration in a TBI mouse model, positively charged peptide-modified nanoparticles accumulated more in off-target organs, including the heart, lung, and kidneys, than zwitterionic, neutral, or negatively charged peptide-modified nanoparticles. The increase in off-target organ accumulation of positively charged peptide-modified nanoparticles was concomitant with a relative decrease in accumulation in the injured brain compared to zwitterionic, neutral, or negatively charged peptide-modified nanoparticles. Understanding how nanoparticle pharmacokinetics are influenced by the physicochemical properties of peptides presented on the nanoparticle surface is relevant to the development of nanoparticle-based TBI therapeutics and broadly applicable to nanotherapeutic design, including synthetic nanoparticles and viruses. Graphical abstractKeywords
This publication has 79 references indexed in Scilit:
- Long-term effects of mild traumatic brain injury on cognitive performanceFrontiers in Human Neuroscience, 2013
- Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered NanoparticlesPLOS ONE, 2011
- Advances in the measurement of protein mobility using laser Doppler electrophoresis - the diffusion barrier techniqueElectrophoresis, 2011
- Surface Charge Affects Cellular Uptake and Intracellular Trafficking of Chitosan-Based NanoparticlesBiomacromolecules, 2011
- Nanoparticle PEGylation for imaging and therapyNanomedicine, 2011
- The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticlesBiomaterials, 2011
- Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategiesTrends in Pharmacological Sciences, 2010
- Effect of Nanoparticle Surface Charge at the Plasma Membrane and BeyondNano Letters, 2010
- Nanoparticle size and surface properties determine the protein corona with possible implications for biological impactsProceedings of the National Academy of Sciences of the United States of America, 2008
- Biomimetic amplification of nanoparticle homing to tumorsProceedings of the National Academy of Sciences of the United States of America, 2007